Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gyre Therapeutics (GYRE) Dividends payables (2022)

Gyre Therapeutics (GYRE) has disclosed Dividends payables for 1 consecutive years, with $7.6 million as the latest value for Q4 2022.

On a quarterly basis, Dividends payables changed N/A to $7.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $7.6 million, a N/A change, with the full-year FY2022 number at $7.6 million, changed N/A from a year prior.
Dividends payables was $7.6 million for Q4 2022 at Gyre Therapeutics.
In the past five years, Dividends payables ranged from a high of $7.6 million in Q4 2022 to a low of $7.6 million in Q4 2022.